{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:42Z","timestamp":1787020182322,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12886-015-0148-2","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T09:14:29Z","timestamp":1446196469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study"],"prefix":"10.1186","volume":"15","author":[{"name":"for the Ozurdex MEAD Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehia","family":"Hashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Whitcup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,30]]},"reference":[{"key":"148_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"148_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1755-3768.2008.01501.x","volume":"88","author":"R Ehrlich","year":"2010","unstructured":"Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88:279\u201391.","journal-title":"Acta Ophthalmol"},{"key":"148_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","volume":"30","author":"J Tang","year":"2011","unstructured":"Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343\u201358.","journal-title":"Prog Retin Eye Res"},{"key":"148_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73\u20139.","journal-title":"Ophthalmology"},{"key":"148_CR5","doi-asserted-by":"publisher","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","volume":"96","author":"K Miyamoto","year":"1999","unstructured":"Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96:10836\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"148_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10456-007-9067-z","volume":"10","author":"KK Erickson","year":"2007","unstructured":"Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10:103\u201317.","journal-title":"Angiogenesis"},{"key":"148_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796\u2013806.","journal-title":"Arch Ophthalmol"},{"key":"148_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","unstructured":"Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447\u20139. 1449.e1\u201310.","journal-title":"Ophthalmology"},{"key":"148_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064\u201377. e35.","journal-title":"Ophthalmology"},{"key":"148_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325.","journal-title":"Ophthalmology"},{"key":"148_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/2042018813512360","volume":"4","author":"DS Boyer","year":"2013","unstructured":"Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151\u201369.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"148_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"148_CR13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1248\/bpb.31.1541","volume":"31","author":"K Wang","year":"2008","unstructured":"Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008;31:1541\u20136.","journal-title":"Biol Pharm Bull"},{"key":"148_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1167\/iovs.04-0905","volume":"46","author":"H Tamura","year":"2005","unstructured":"Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46:1440\u20134.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"148_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1046\/j.0022-3042.2001.00740.x","volume":"80","author":"DA Antonetti","year":"2002","unstructured":"Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto Jr RC. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80:667\u201377.","journal-title":"J Neurochem"},{"key":"148_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ophtha.2010.09.029","volume":"118","author":"MC Gillies","year":"2011","unstructured":"Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011;118:866\u201372.","journal-title":"Ophthalmology"},{"key":"148_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","volume":"118","author":"MJ Elman","year":"2011","unstructured":"Elman MJ, Bressler NM, Qin H, Beck RW, Ferris 3rd FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609\u201314.","journal-title":"Ophthalmology"},{"key":"148_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1586\/eop.10.82","volume":"6","author":"BD Kuppermann","year":"2011","unstructured":"Kuppermann BD. Sustained-release dexamethasone intravitreal implant for treatment of diabetic macular edema. Expert Rev Ophthalmol. 2011;6:11\u201320.","journal-title":"Expert Rev Ophthalmol"},{"key":"148_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archopht.125.3.309","volume":"125","author":"BD Kuppermann","year":"2007","unstructured":"Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309\u201317.","journal-title":"Arch Ophthalmol"},{"key":"148_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"148_CR21","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort Jr R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904\u201314.","journal-title":"Ophthalmology"},{"key":"148_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134\u201346. e3.","journal-title":"Ophthalmology"},{"key":"148_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/eye.2013.287","volume":"28","author":"R Mathew","year":"2014","unstructured":"Mathew R, Pearce E, Muniraju R, Abdel-Hay A, Sivaprasad S. Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). Eye (Lond). 2014;28:318\u201326.","journal-title":"Eye (Lond)"},{"key":"148_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000356413","volume":"231","author":"M Dutra Medeiros","year":"2014","unstructured":"Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arum\u00ed J, Mateo C, Corc\u00f3stegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231:141\u20136.","journal-title":"Ophthalmologica"},{"key":"148_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/IAE.0b013e3182a48958","volume":"34","author":"R Lazic","year":"2014","unstructured":"Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34:719\u201324.","journal-title":"Retina"},{"key":"148_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","volume":"31","author":"DS Boyer","year":"2011","unstructured":"Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915\u201323.","journal-title":"Retina"},{"key":"148_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/jop.2014.0010","volume":"30","author":"MD Medeiros","year":"2014","unstructured":"Medeiros MD, Alkabes M, Navarro R, Garcia-Arum\u00ed J, Mateo C, Corc\u00f3stegui B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther. 2014;30:709\u201316.","journal-title":"J Ocul Pharmacol Ther"},{"key":"148_CR28","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013\u201322.","journal-title":"Ophthalmology"},{"key":"148_CR29","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3\u00a0years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125\u201332.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-015-0148-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T06:59:21Z","timestamp":1475823561000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-015-0148-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1186\/s12886-015-0148-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,30]]},"article-number":"150"}}